According to a post on the FDA’s website, Calliditas Therapeutics received orphan designation for its treatment of Alport syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CALT:
- H.C. Wainwright keeps $50 target on Calliditas after Travere data
- Calliditas Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
- Calliditas Therapeutics price target lowered to $18 from $21 at Guggenheim
- Calliditas Therapeutics announces FDA acceptance of Tarpeyo sNDA
- Calliditas Therapeutics’ NefIgArd phase 3 trial results published in The Lancet